Cargando…
Regulation of Ferroptosis in Lung Adenocarcinoma
Lung adenocarcinoma (LUAD) is the most common lung cancer, which accounts for about 35–40% of all lung cancer patients. Despite therapeutic advancements in recent years, the overall survival time of LUAD patients still remains poor, especially KRAS mutant LUAD. Therefore, it is necessary to further...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572737/ https://www.ncbi.nlm.nih.gov/pubmed/37834062 http://dx.doi.org/10.3390/ijms241914614 |
_version_ | 1785120302617853952 |
---|---|
author | Wei, Xiangyun Li, Xiaohe Hu, Shuming Cheng, Jinke Cai, Rong |
author_facet | Wei, Xiangyun Li, Xiaohe Hu, Shuming Cheng, Jinke Cai, Rong |
author_sort | Wei, Xiangyun |
collection | PubMed |
description | Lung adenocarcinoma (LUAD) is the most common lung cancer, which accounts for about 35–40% of all lung cancer patients. Despite therapeutic advancements in recent years, the overall survival time of LUAD patients still remains poor, especially KRAS mutant LUAD. Therefore, it is necessary to further explore novel targets and drugs to improve the prognos is for LUAD. Ferroptosis, an iron-dependent regulated cell death (RCD) caused by lipid peroxidation, has attracted much attention recently as an alternative target for apoptosis in LUAD therapy. Ferroptosis has been found to be closely related to LUAD at every stage, including initiation, proliferation, and progression. In this review, we will provide a comprehensive overview of ferroptosis mechanisms, its regulation in LUAD, and the application of targeting ferroptosis for LUAD therapy. |
format | Online Article Text |
id | pubmed-10572737 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-105727372023-10-14 Regulation of Ferroptosis in Lung Adenocarcinoma Wei, Xiangyun Li, Xiaohe Hu, Shuming Cheng, Jinke Cai, Rong Int J Mol Sci Review Lung adenocarcinoma (LUAD) is the most common lung cancer, which accounts for about 35–40% of all lung cancer patients. Despite therapeutic advancements in recent years, the overall survival time of LUAD patients still remains poor, especially KRAS mutant LUAD. Therefore, it is necessary to further explore novel targets and drugs to improve the prognos is for LUAD. Ferroptosis, an iron-dependent regulated cell death (RCD) caused by lipid peroxidation, has attracted much attention recently as an alternative target for apoptosis in LUAD therapy. Ferroptosis has been found to be closely related to LUAD at every stage, including initiation, proliferation, and progression. In this review, we will provide a comprehensive overview of ferroptosis mechanisms, its regulation in LUAD, and the application of targeting ferroptosis for LUAD therapy. MDPI 2023-09-27 /pmc/articles/PMC10572737/ /pubmed/37834062 http://dx.doi.org/10.3390/ijms241914614 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Wei, Xiangyun Li, Xiaohe Hu, Shuming Cheng, Jinke Cai, Rong Regulation of Ferroptosis in Lung Adenocarcinoma |
title | Regulation of Ferroptosis in Lung Adenocarcinoma |
title_full | Regulation of Ferroptosis in Lung Adenocarcinoma |
title_fullStr | Regulation of Ferroptosis in Lung Adenocarcinoma |
title_full_unstemmed | Regulation of Ferroptosis in Lung Adenocarcinoma |
title_short | Regulation of Ferroptosis in Lung Adenocarcinoma |
title_sort | regulation of ferroptosis in lung adenocarcinoma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572737/ https://www.ncbi.nlm.nih.gov/pubmed/37834062 http://dx.doi.org/10.3390/ijms241914614 |
work_keys_str_mv | AT weixiangyun regulationofferroptosisinlungadenocarcinoma AT lixiaohe regulationofferroptosisinlungadenocarcinoma AT hushuming regulationofferroptosisinlungadenocarcinoma AT chengjinke regulationofferroptosisinlungadenocarcinoma AT cairong regulationofferroptosisinlungadenocarcinoma |